Repatha

Company snapshot

Repatha is a pharma organization headquartered in JP. Primary therapeutic focus areas include Influenza, Encephalitis, Japanese B, Malaria, Vivax. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTrials.gov, and USPTO sources. Pipeline phase mix: phase 1 (1), phase 3 (1), approved (1).

• 3 active pipeline program(s) linked via ClinicalTrials.gov.
• 3 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for Repatha. Not investment advice.

• What is Repatha?

  Repatha is a pharma organization headquartered in JP. Primary therapeutic focus areas include Influenza, Encephalitis, Japanese B, Malaria, Vivax. NovaPharmaNews links 3 clinical program(s), 0 drug profile(s), and 0 patent record(s) to this entity from public FDA, EMA, ClinicalTr

• Is Repatha publicly traded?

  Repatha appears in our database through regulatory marketing authorisation or clinical trial sponsor records; a US listed ticker is not shown for this entity.

• What drugs does Repatha develop or market?

  We link 6 drug profile(s) where Repatha is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/repatha#company-drugs.

• What are the latest developments for Repatha?

  In the last 12 months our linked public records show 3 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does Repatha focus on?

  Repatha focuses on Influenza, Encephalitis, Japanese B, Malaria, Vivax based on our analysis of their pipeline programs and drug development activities.